This section highlights FDA-related milestones and regulatory updates for drugs developed by AstraZeneca (AZNCF).
Over the past two years, AstraZeneca has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Durvalumab, TAGRISSO®, NeXT, casdatifan, and capivasertib. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Durvalumab FDA Regulatory Timeline and Events
Durvalumab is a drug developed by AstraZeneca for the following indication: Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Durvalumab
- Announced Date:
- November 13, 2026
- Indication:
- Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy
Announcement
AstraZeneca’s IMFINZI® (durvalumab) in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy.
AI Summary
The US FDA approved AstraZeneca’s IMFINZI (durvalumab) with enfortumab vedotin-ejfv (EV) before surgery, followed by IMFINZI alone after surgery, for adults with muscle-invasive bladder cancer (MIBC) who cannot receive or have declined cisplatin-based chemotherapy. Treatment includes three cycles of the combination before bladder removal, then nine cycles of IMFINZI.
The approval is based on the Phase III VOLGA trial. Compared with surgery with or without approved follow-up treatment, the regimen lowered the risk of disease progression, recurrence, not having surgery, or death by 49%. It also reduced the risk of death by 42%. At two years, 64% of patients receiving the regimen were alive without these events, compared with 45% in the comparison group; 78% were alive, compared with 69%.
Safety was manageable, with no new safety concerns identified. The findings offer a treatment option for patients who are not candidates for cisplatin chemotherapy.
Read Announcement- Drug:
- Durvalumab
- Announced Date:
- October 27, 2026
- Indication:
- Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy
Announcement
Innate Pharma SA announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously.
Read Announcement- Drug:
- Durvalumab
- Announced Date:
- October 24, 2026
- Indication:
- Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy
Announcement
Astrazeneca announced Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care.
Read Announcement- Drug:
- Durvalumab
- Announced Date:
- October 19, 2026
- Indication:
- Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy
Announcement
AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 23-27, 2026.
AI Summary
AstraZeneca will present more than 100 research abstracts at the European Society for Medical Oncology (ESMO) Congress, October 23–27, 2026. The program includes results from five pivotal Phase III trials, with four featured in Presidential Symposia. The data span bladder, lung and gastric cancers and highlight precision treatments, drug combinations and antibody-drug conjugates.
CLARITY-Gastric01 showed a meaningful overall-survival benefit for Sone-Ve in later-line treatment of CLDN18.2-positive advanced gastric or gastroesophageal cancer, a group that includes about 60% of patients in this setting. SAFFRON will present results for adding savolitinib to TAGRISSO in MET-driven, EGFR-mutated lung cancer after prior treatment. VOLGA and DeLLphi-305 will examine IMFINZI combinations in bladder and small cell lung cancers. Other presentations include studies of novel cancer medicines, blood-based tumor testing and CAR-T cell therapy, demonstrating the breadth of AstraZeneca’s portfolio and research pipeline.
Read Announcement
TAGRISSO® (osimertinib) FDA Regulatory Events
TAGRISSO® (osimertinib) is a drug developed by AstraZeneca for the following indication: Third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- TAGRISSO® (osimertinib)
- Announced Date:
- October 25, 2026
- Indication:
- Third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases.
Announcement
AstraZeneca Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Read Announcement
NeXT Personal FDA Regulatory Events
NeXT Personal is a drug developed by AstraZeneca for the following indication: in patients with unresectable stage III, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- NeXT Personal
- Announced Date:
- October 21, 2026
- Indication:
- in patients with unresectable stage III, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Announcement
Personalis, Inc announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3 study in cutaneous squamous cell carcinoma, as well as a Rapid Oral presentation from B-STRONGER-1, a prospective, multicenter study evaluating NeXT Personal for detecting molecular residual disease in patients with early-stage triple-negative breast cancer receiving neoadjuvant therapy.
AI Summary
Personalis, Inc. will present four studies featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test at the European Society for Medical Oncology Congress, October 23–27, 2026, in Madrid. The program includes two oral presentations and two posters.
A key highlight is a late-breaking oral presentation of ctDNA findings from the C-POST Phase 3 study. The study evaluates adjuvant cemiplimab versus placebo in people with high-risk cutaneous squamous cell carcinoma, and the presentation will include updated survival results and ctDNA analyses.
A Rapid Oral presentation will share early results from B-STRONGER-1, a prospective, multicenter study of people with early-stage triple-negative breast cancer receiving treatment before surgery. Researchers are assessing whether NeXT Personal can track early ctDNA changes and detect molecular residual disease—small traces of cancer that may remain after treatment.
Personalis says the presentations add to research on using ultrasensitive ctDNA testing to monitor treatment and support drug development across different cancers. The findings are study results and do not establish the test’s clinical benefit.
Read Announcement
Casdatifan FDA Regulatory Events
Casdatifan is a drug developed by AstraZeneca for the following indication: In patients with ccRCC.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- casdatifan
- Announced Date:
- October 20, 2026
- Indication:
- In patients with ccRCC
Announcement
Arcus Biosciences, Inc announced new data at an investor event in New York City from the ARC-20 platform study, which is evaluating casdatifan, an investigational next-generation HIF-2α inhibitor, alone or in combination, as a first-, second- and late-line treatment for clear cell renal cell carcinoma (ccRCC).
AI Summary
Arcus Biosciences reported new results from its ARC-20 study of casdatifan, an investigational HIF-2α inhibitor for clear cell kidney cancer. In the first-line group, casdatifan plus zimberelimab showed 86% of patients free from disease progression at six months and 69% at 12 months, above third-party benchmarks for some standard treatments. Half of patients had a confirmed tumor response. A three-drug combination had few cases of early progression, and Arcus expects to begin the Phase 3 PEAK-20 trial by year-end.
In second-line patients, casdatifan plus cabozantinib achieved median progression-free survival of 14.5 months and an 18-month survival rate of 77%, exceeding benchmarks for cabozantinib alone. Results were similar in patients previously treated with a TKI; the combination is being tested in Phase 3 PEAK-1. In heavily treated patients receiving casdatifan alone, median overall survival reached 35 months—more than a year above a benchmark for the only approved HIF-2α inhibitor. Arcus plans a registration trial of casdatifan plus tivozanib. Comparisons use separate studies, not head-to-head trials.
Read Announcement
Capivasertib FDA Regulatory Events
Capivasertib is a drug developed by AstraZeneca for the following indication: In patients with locally advanced (inoperable) or metastatic triple-negative breast cancer.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- capivasertib
- Announced Date:
- November 25, 2024
- Indication:
- In patients with locally advanced (inoperable) or metastatic triple-negative breast cancer
Announcement
AstraZeneca announced that Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).
AI Summary
AstraZeneca announced positive high-level results from the CAPItello-281 Phase III trial. The study found that TRUQAP (capivasertib), when combined with abiraterone and androgen deprivation therapy (ADT), significantly improved radiographic progression-free survival (rPFS) compared to abiraterone and ADT with a placebo. This trial specifically focused on patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, an aggressive form with poor outcomes.
Although overall survival data remains immature, early trends suggest a potential benefit. This marks the first time an AKT inhibitor has shown benefit in this specific prostate cancer subtype, offering a promising new treatment option for a patient population with limited alternatives.
Read Announcement